Fierce Pharma July 21, 2011 — 10:29am ET | By Tracy Staton Merck’s ($MRK) Gardasil journey is becoming a saga, with twists and turns all over the place. When first approved, the vaccine against human papillomavirus was tagged as a no-brainer blockbuster. But uptake of the vaccine hit a snag; after about a third of eligible […]